CRYSTALLINE FORM OF N-CYCLOPROPYL-3-FLUORO-4-METHYL-5-[3-[[1-[2-[2-(METHYLAMINO)ETHOXY]PHENYL]CYCLOPROPYL]AMINO]-2-OXO-1(2H)-PYRAZINYL]­BENZAMIDE

The application relates to a crystalline form of the compound of formula (I) (see formula I) with a number of advantages over the previous Form A. The application also relates to a process for producing the crystalline form, pharmaceutical compositions comprising the crystalline form, and uses of th...

Full description

Saved in:
Bibliographic Details
Main Authors CHAN, LAI CHUN, LANGER, THOMAS, JANBON, SOPHIE, BETHEL, PAUL ALLEN, PERVEZ, MOHAMMED
Format Patent
LanguageEnglish
French
Published 28.07.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The application relates to a crystalline form of the compound of formula (I) (see formula I) with a number of advantages over the previous Form A. The application also relates to a process for producing the crystalline form, pharmaceutical compositions comprising the crystalline form, and uses of the crystalline form for treating diseases, such as chronic obstructive pulmonary disease (COPD) or asthma. L'invention concerne une forme cristalline d'un composé de formule (I).
Bibliography:Application Number: CA20163014357